Cheers guys, the appointment of Bruce Hancox to the board and a pending announcement re Perseis Cancer Research Program, and this comment in the annual re Motiva ""the Company believes that it will have an opportunity to enter into a beneficial commercial partnership to complete the pivotal trials necessary for registration of the drug for that indication."" appears rather timely.
""Commenting on Mr Hancox’s appointment, Dr Robin Congreve, Neuren’s Chairman said “We are
delighted that Bruce has agreed to join Neuren’s board. He will be an important addition to our
presence in Australia. His vast business experience will add significantly to the Board’s capabilities
and in particular its ability to add shareholder value when partnering and licensing opportunities
become available”.""
on the move again...., page-52
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.12 |
Change
0.770(5.37%) |
Mkt cap ! $1.927B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.18 | $14.35 | $4.601M | 308.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 598 | $15.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.13 | 280 | 11 |
View Market Depth
| Last trade - 14.41pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |